The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Abstract
This study characterized single‐ and multiple‐dose pharmacokinetics of canagliflozin and its O‐glucuronide metabolites (M5 and M7) and pharmacodynamics (renal threshold for glucose [RT G], urinary glucose excretion [UGE 0–24h], and 24‐hour mean plasma glucose [MPG 0–24h]) of canagliflozin in subjects with type 2 diabetes. Thirty‐six randomized subjects received canagliflozin 50, 100, or 300 mg/day or placebo for 7 days. On Days 1 and 7, area under the plasma concentration‐time curve and maximum observed plasma concentration (C max) for canagliflozin and its metabolites increased dose‐dependently. Half‐life and time at which C max was observed were dose‐independent. Systemic molar M5 exposure was half that of canagliflozin; M7 exposure was similar to canagliflozin. Steady‐state plasma canagliflozin concentrations were reached by Day 4 in all active treatment groups. Pharmacodynamic effects were dose‐ and exposure‐dependent. All canagliflozin doses decreased RT G, increased UGE 0–24h, and reduced MPG 0–24h versus placebo on Days 1 and 7. On Day 7, placebo‐subtracted least‐squares mean decreases in MPG 0–24h ranged from 42–57 mg/dL with canagliflozin treatment. Adverse events (AEs) were balanced between treatments; no treatment‐related serious AEs, AE‐related discontinuations, or clinically meaningful adverse changes in routine safety evaluations occurred. The observed pharmacokinetic/pharmacodynamic profile of canagliflozin in subjects with type 2 diabetes supports a once‐daily dosing regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Cited by
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Functional expression of sodium-glucose transporters in cancer
Scafoglio, C., Hirayama, B. A., Kepe, V., Liu, J., Ghezzi, C., Satyamurthy, N., Moatamed, N. A., Huang, J., Koepsell, H., Barrio, J. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511698112 · Cited by 329
Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T. P., Ghosh, A., Vaccaro, N., Farrell, K., Rothenberg, P., & Henry, R. R. (2013) · Diabetes Care · doi:10.2337/dc12-2391 · Cited by 261
Self-citationLi, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 253
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Self-citationHerrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
Polidori, D., Sanghvi, A., Seeley, R. J., & Hall, K. D. (2016) · Obesity · doi:10.1002/oby.21653 · Cited by 209
Self-citationScafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5933 · Cited by 176
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Hallow, K. M., Gebremichael, Y., Helmlinger, G., & Vallon, V. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00497.2016 · Cited by 98
Sinclair, A. J., Bode, B., Harris, S., Vijapurkar, U., Shaw, W., Desai, M., & Meininger, G. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14028 · Cited by 87
Iijima, H., Kifuji, T., Maruyama, N., & Inagaki, N. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0234-0 · Cited by 70
“These pharmacodynamic profiles of canagliflozin in Japanese patients were also similar to those in studies with non-Japanese patients [3, 20, 22, 24].”
BackgroundResultExamining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
Metadata
- Authors
- Devineni, D., Curtin, C. R., Polidori, D., Gutierrez, M. J., Murphy, J., Rusch, S., & Rothenberg, P. L.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-05-14
- Volume
- 53
- Issue
- 6
- Pages
- 601-610
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1606165384
- Cited by
- 217
- References
- 3
- FWCI
- 21.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.